HF3708 clarifies how Minnesota will evaluate whether its reverse-auction pharmacy benefit manager (PBM) contract actually produced prescription drug savings before deciding whether to use that procurement method again. The bill requires the commissioner of management and budget, with an actuarial consultant, to compare actual drug costs under the current PBM contract against a projected cost under the prior 2018-2022 contract, using industry-recognized data sources and adjusting for formulary or utilization changes. The commissioner must report the comparison to the legislative auditor and legislative committee leaders, and the legislative auditor must then verify whether the comparison was performed accurately.
The bill also sets out what happens after that review. If the comparison shows savings were not achieved, or is inconclusive, the commissioner may skip the reverse-auction process when selecting a successor PBM contract. If savings were achieved, the commissioner must use the reverse-auction process for the next contract. The bill further requires the consultant to avoid conflicts of interest and directs the technology platform vendor to provide prescription drug data and related support, while protecting individual-identifying data as private data.
Impact
HF3708 amends Minnesota Statutes 2024, section 43A.231, subdivision 5, by refining the state’s PBM procurement and oversight process. It adds reporting, audit, and data-sharing requirements tied to the state’s reverse-auction PBM contract, and it gives the commissioner of management and budget discretion to bypass reverse auction if the required savings test is not met or cannot be conclusively determined. The bill affects state procurement practices, the commissioner of management and budget, the legislative auditor, actuarial consultants, and the technology platform vendor handling prescription drug data.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the measure appears to be a technical and oversight-focused clarification rather than a highly controversial policy change. Its structure suggests an intent to ensure accountability and verify whether the state’s PBM contracting approach is delivering promised savings. No recorded opposition or support is available in the provided materials, so the overall sentiment cannot be measured from debate or voting history.
Contention
The main point of potential contention is the reverse-auction PBM model itself: supporters are likely to favor the bill’s emphasis on measuring savings and preserving the process only if it works, while critics may question whether the comparison methodology is reliable or whether reverse auctions are the best way to manage prescription drug costs. Another possible issue is the role of the actuarial consultant and the need to guard against conflicts of interest, which indicates sensitivity around the independence and credibility of the savings analysis. Data privacy may also be a concern because the bill requires the vendor to share prescription drug data, though it expressly protects individual-identifying information as private data.
Pharmacy benefit managers and health carriers usage of prescription drug rebates and other compensation requirement to benefit covered persons provision
Article V Convention; process for appointing commissioners and alternate commissioners to represent the State of Alabama at Article V Convention established